National Health (Pharmaceutical Benefits) Regulations (Amendment)

Overview

Statutory Rules 1964, No. 12, made under the National Health Act 1953, was enacted to amend the National Health (Pharmaceutical Benefits) Regulations. These regulations were introduced to address the need for updating the list of approved pharmaceutical benefits provided under the National Health Act, ensuring that the list reflects the current medical needs and available treatments. Enacted by the Governor-General in accordance with the advice of the Federal Executive Council, the regulations aim to ensure that the Pharmaceutical Benefits Scheme remains relevant and effective in providing necessary medications to Australians. This legislative instrument was designed to enhance the accessibility and coverage of essential medicines, aligning with the overarching policy objective of improving public health outcomes.

Scope and Application

The National Health (Pharmaceutical Benefits) Regulations, as amended, apply to a broad range of stakeholders, including individuals, healthcare providers, and pharmaceutical companies within the Commonwealth of Australia. These regulations, which are subordinate to the overarching National Health Act 1953-1963, govern the pharmaceutical benefits scheme by detailing which medications are covered under the scheme and the conditions for their coverage. The regulations impact a wide array of entities such as patients who seek subsidised medication, healthcare practitioners who prescribe these medications, and pharmaceutical companies that manufacture and supply them. The amendments outlined in the statutory rules focus on the inclusion and exclusion of specific pharmaceutical products from the benefits schedule, thereby directly influencing the accessibility and affordability of these medications. These regulations apply nationwide, ensuring a uniform approach to pharmaceutical benefits across the country. However, they do not explicitly state exclusions or thresholds beyond the specified additions and deletions of pharmaceutical items, leaving some room for interpretation or further clarification through subordinate instruments.

Key Provisions

These Regulations, made under the National Health Act 1953-1963, come into effect on 1 February 1964. The primary purpose of these Regulations is to amend the National Health (Pharmaceutical Benefits) Regulations by updating the list of pharmaceutical items covered by the scheme. This is achieved through amendments to various schedules of the existing Regulations (reg 2). Specifically, several new pharmaceutical items are added to the list, including Almond Oil, Aloes, Ferrous Gluconate, Halibut Liver Oil, Kaolin Heavy, Malt Extract, Piperazine Adipate, Piperazine Phosphate, Scarlet Fever Prophylactic, Schick Control, Sodium Bicarbonate Injection, Solution Chlorinated Soda Surgical, Stibophen, Stibophen Injection, Stramonium Powdered, Tryparsamide Injection, and Typhoid-Paratyphoid A, B and C Vaccine. Concurrently, some items are removed from the list, such as Adrenaline Hydrochloride Solution, B.P. 1953, Charcoal, Colocynth, B.P.C., Erythrityltetranitrate, B.P.C. 1949, Fructose, B.P. 1948, Glucose, Liquid, B.P. 1953, Iodoform Suppository, B.P. 1948, Ox-Bile Extract, B.P. 1948, Quassia Tincture, B.P. 1948, and Vitamin K (reg 3). These amendments impose an obligation on pharmaceutical entities to update their records and ensure that the newly listed pharmaceutical items are available for prescription and reimbursement under the National Health scheme. Healthcare providers and patients must also be informed of these changes to ensure compliance with the updated list. The Regulations do not explicitly state any specific obligations or requirements for parties governed by them beyond these updates to the pharmaceutical list. There are no explicit provisions detailing offences, penalties, or consequences for non-compliance with these Regulations within the text provided. However, non-compliance with the National Health Act 1953-1963 and its subordinate legislation could potentially lead to enforcement actions under the general provisions of the Act, which might include fines, penalties, or other legal consequences as deemed appropriate by the relevant authorities.